Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.110020 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.110020 32590326!7833517!32590326     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2020 ; 144 (ä): 110020 Nephropedia Template TP {{tp|p=32590326|t=2020. Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 |pdf=|usr=}}{{32590326}} gab.com Text Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32590326 #FOAvip Pulmonary surfactant is considered to be one of the soaps. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the other enveloped viruses become very weak against surfactant. The SARS virus binds to angiotensin-converting enzyme (ACE2) receptor and causes pneumonia. In the lung, the ACE2 receptor sits on the top of lung cells known as alveolar epithelial type II (AE2) cells. These cells play an important role in producing surfactant. Pulmonary surfactant is believed to regulate the alveolar surface tension in mammalian lungs. To our knowledge, AE2 cells are believed to act as immunoregulatory cells; however, pulmonary surfactant itself has not been believed to act as a defender against the enveloped viruses. This study hypothesises that pulmonary surfactant may be a strong defender of enveloped viruses. Therefore, old coronaviruses merely cause pneumonia. On the contrary, new SARS-CoV-2 can suppress the production of surfactant that binds to the ACE2 of AE2 cells. The coronavirus can survive in the lung tissue because of the exhaustion of pulmonary surfactant. Twit Text FOAVip Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32590326 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32590326 #FOAvip English Wikipedia <ref>{{Cite pmid|32590326}}</ref> Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 #MMPMID32590326 Takano H Med Hypotheses 2020[Nov]; 144 (ä): 110020 PMID32590326show ga Pulmonary surfactant is considered to be one of the soaps. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the other enveloped viruses become very weak against surfactant. The SARS virus binds to angiotensin-converting enzyme (ACE2) receptor and causes pneumonia. In the lung, the ACE2 receptor sits on the top of lung cells known as alveolar epithelial type II (AE2) cells. These cells play an important role in producing surfactant. Pulmonary surfactant is believed to regulate the alveolar surface tension in mammalian lungs. To our knowledge, AE2 cells are believed to act as immunoregulatory cells; however, pulmonary surfactant itself has not been believed to act as a defender against the enveloped viruses. This study hypothesises that pulmonary surfactant may be a strong defender of enveloped viruses. Therefore, old coronaviruses merely cause pneumonia. On the contrary, new SARS-CoV-2 can suppress the production of surfactant that binds to the ACE2 of AE2 cells. The coronavirus can survive in the lung tissue because of the exhaustion of pulmonary surfactant. |*SARS-CoV-2[MESH] |Ambroxol/therapeutic use[MESH] |Angiotensin-Converting Enzyme 2/*metabolism[MESH] |Bromhexine/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*physiopathology/*prevention & control[MESH] |Clinical Trials as Topic[MESH] |Crystallography, X-Ray[MESH] |Humans[MESH] |Models, Theoretical[MESH] |Phagocytosis[MESH] |Pneumonia, Viral/*physiopathology[MESH] |Pregnenediones/therapeutic use[MESH] |Pulmonary Alveoli/metabolism[MESH] |Pulmonary Surfactants/*therapeutic use[MESH] |Surface Tension[MESH]Pulmonary surfactant itself must be a strong defender against SARS-CoV(epmc).pdf DeepDyve Pubget Overpricing